… Like most cancers, lung cancer is a conglomeration … -cell lung cancer (SCLC, comprising
20% of lung cancers), and non-small-cell lung cancer (NSCLC, comprising 80% of lung cancers…

… growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
… EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and …

… mutations have recently been reported in some patients with small cell lung cancers (SCLC)…
In this study, we first examined a large series of SCLCs to address mutation incidence. …

… The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …

… We prospectively screened 2105 patients with non–small-cell lung cancer for EGFR mutations.
Patients with mutations were then considered for erlotinib treatment at a dose of 150 mg …

… lung cancers are classified into two major types, small cell lung cancer (SCLC) and non–small
cell lung cancer (… adenocarcinoma and squamous cell carcinoma. Previously, squamous …

… the epidermal growth factor receptor gene (EGFR) in patients with non–small-cell lung …
non–small-cell lung cancers previously identified as having the EGFR mutation and 8 specimens …

… in patients with non–small cell lung cancer. Since then, multiple groups … mutations confer
as well as the clinical relevance of these mutations in patients with non–small cell lung cancer. …

… Mutations in non–small-cell lung cancers have been found in [1] epidermal growth factor
receptor … Only EGFR tyrosine kinase domain mutations are associated with sensitivity to gefitinib …

… growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) is …
This meta-analysis was conducted to provide a worldwide overview of EGFR mutation and …